Advertisement
Advertisement
INDV
Indivior Pharmaceuticals, Inc. Common Stock
36.87
USDSponsored
-0.91
-2.41%
Aug 21, 15:59 UTC -4
Closed
After-Market
36.84
-0.03
-0.09%
INDV Earnings Reports
Positive Surprise Ratio
INDV beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$333.23M
/$1.03
Implied change from Q2 26 (Revenue/ EPS)
-2.85%
/-9.65%
Implied change from Q3 25 (Revenue/ EPS)
+6.13%
/+43.06%
Indivior Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 03, 2026, INDV reported earnings of 1.14 USD per share (EPS) for Q2 26, beating the estimate of 0.89 USD, resulting in a 28.97% surprise. Revenue reached 343.00 million, compared to an expected 313.70 million, with a 9.34% difference. The market reacted with a -2.33% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of 1.03 USD, with revenue projected to reach 333.23 million USD, implying an decrease of -9.65% EPS, and decrease of -2.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Indivior Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Indivior Pharmaceuticals, Inc. Common Stock reported EPS of $1.14, beating estimates by 28.97%, and revenue of $343.00M, 9.34% above expectations.
How did the market react to Indivior Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -2.33%, changed from $37.37 before the earnings release to $36.50 the day after.
When is Indivior Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Indivior Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 5
analysts, Indivior Pharmaceuticals, Inc. Common Stock is expected to report EPS of $1.03 and revenue of $333.23M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement